ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mitiglinide

Also written as “Mitiglinide”, “KAD-1229” and “mitiglinide and metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, led by 4 companies.

Drug pageMitiglinide: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 30, 20147 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kissei Pharmaceuticalits history only30 open or runningphase 4since May 30, 2014Apr 17, 2007none ahead
JW Pharmaceutical20 open or runningphase 4since Apr 18, 2008Apr 18, 2008none ahead
Elixir Pharmaceuticalsits history only10 open or runningphase 3since Aug 20, 2007Aug 20, 2007none ahead
Orient Europharmaits history only10 open or runningphase 4since Mar 3, 2020Mar 3, 2020none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of JW Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2008First study: phase 4 study in Diabetes Mellitus, Type 2First studyNCT00663884 · 167 enrolled · Korea, Republic of
  2. Sep 27, 2011Phase 1 study in HealthyNCT01443221 · 24 enrolled · Korea, Republic of

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
repaglinideruleNovo Nordiskphase 432

Studies

All 2 JW Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01443221Healthy · Korea, Republic of1CompletedJan 201124
NCT00663884Diabetes Mellitus, Type 2 · Korea, Republic of4CompletedJul 2009167

How it is read

Names in the registry

  • “Mitiglinide”, 4 entries
  • “KAD-1229”, 2 entries
  • “mitiglinide and metformin”, 2 entries
  • “mitiglinide”, 2 entries
  • “Mitiglinide calcium hydrate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.